top of page

Health & Pharmaceutical

当社の専門知識

Mahendra & Co. specializes in providing comprehensive legal services to clients in the health industry. Our team of experienced attorneys is well-versed in the legal requirements governing healthcare, pharmaceuticals, and medical law. We are dedicated to offering the best legal advice to help our clients navigate the complex and evolving regulatory landscape of the health sector.

Our health law services include:
- Advising on medical law, including patient rights, healthcare provider obligations, and medical malpractice
- Assisting with the application and renewal of health and pharmaceutical licenses
- Drafting and reviewing pharmaceutical and healthcare agreements, including distribution and supply contracts
- Ensuring compliance with regulatory standards, including food and drug safety regulations
- Providing legal guidance on the establishment and operation of healthcare facilities, such as hospitals and clinics
- Representing clients in disputes related to healthcare practices, medical negligence, and regulatory violations
- Offering strategic legal counsel on mergers, acquisitions, and joint ventures within the healthcare and pharmaceutical sectors

With our deep understanding of healthcare regulations and industry-specific legal challenges, we are committed to supporting our clients in maintaining compliance and achieving their business goals in the health industry.

Contact us to discuss how we can provide legal solutions tailored to your healthcare or pharmaceutical needs.

当社について詳しく読むクライアントとプロジェクト 私たちが提供したものを学ぶために。

最新の洞察

2026年4月17日

Transisi KBLI 2025 di Indonesia: Hal yang Perlu Diketahui Pelaku Usaha

Transisi KBLI 2025 di Indonesia: Hal yang Perlu Diketahui Pelaku Usaha

Indonesia mulai menerapkan KBLI 2025 pada 18 Juni 2026, menggantikan KBLI 2020 berdasarkan Peraturan BPS No. 7/2025 untuk mendukung perizinan berbasis risiko (OSS).

Transisi KBLI 2025 di Indonesia: Hal yang Perlu Diketahui Pelaku Usaha

2026年4月17日

Indonesia mulai menerapkan KBLI 2025 pada 18 Juni 2026, menggantikan KBLI 2020 berdasarkan Peraturan BPS No. 7/2025 untuk mendukung perizinan berbasis risiko (OSS).

KBLI 2025 Transition in Indonesia: What Businesses Need to Know

2026年4月17日

Indonesia to implement KBLI 2025 starting June 18, 2026, replacing KBLI 2020 under BPS Regulation No. 7/2025 to support risk-based licensing (OSS).

Pembaharuan Modal PT PMA: Komitmen Minimum Modal Ditempatkan/Disetor Rp 2,5 Miliar dalam Peraturan BKPM 5/2025

2025年10月6日

Peraturan BKPM 5/2025 menetapkan komitmen permodalan minimum yang lebih tegas bagi Penanaman Modal Asing (PMA) di Indonesia, dengan mewajibkan modal ditempatkan/disetor paling sedikit Rp2,5 miliar per perseroan terbatas serta penguncian dana selama 12 bulan. Selain itu, regulasi ini memperkuat kepastian hukum dan disiplin investasi melalui ketentuan nilai investasi minimum lebih dari Rp10 miliar per bidang usaha KBLI dan lokasi proyek, disertai dengan pengecualian sektoral yang terstruktur.
bottom of page